Varian (NYSE:VAR) spotted trading -23.82% off 52-week high price. On the other end, the stock has been noted 7.03% away from the low price over the last 52-weeks. The stock changed 0.45% to recent value of $108.55. The stock transacted 601899 shares during most recent day however it has an average volume of 593.64K shares. The company has 91M of outstanding shares and 90.8M shares were floated in the market.
On Aug.21, 2019, Varian (NYSE:VAR) revealed that Phil Febbo, MD, chief medical officer (CMO) at Illumina has been appointed to the Varian Board of Directors, effective August 16, 2019.
We are proud to have Phil Febbo join the Varian Board, said R. Andrew Eckert, chairman of Varian’s Board of Directors. Phil has a strong background in both clinical and research work, as well as company strategy. He will be another valuable member of the Varian Board as the company continues its transformation into the leader in intelligent cancer care.
Varian is a leader in addressing the global cancer challenge by developing innovative solutions that are increasing access to high quality care, said Febbo. It is an exciting time to join the Varian Board, as the company expands beyond its traditional radiotherapy focus and puts the patient and clinician at the center of its thinking to deliver intelligent cancer care. I look forward to joining the Board and being a part of the company’s vision of creating a world without fear of cancer.
Dr. Febbo, 53, has served as CMO at Illumina since 2018 and is responsible for developing and executing the Company’s medical strategy to drive genomic testing into healthcare practice in order to improve health outcomes. Prior to joining Illumina, he served as CMO of Genomic Health for five years where he drove the company’s medical strategy, was accountable for the development of evidence supporting GHI’s proprietary tests, engaged with the payer community to drive reimbursement, and served as a corporate officer between 2016 and 2018. Prior to Genomic Health, Dr. Febbo was a Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology. He currently serves on the board of the American College of Medical Genetics and Genomics Foundation.
Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College and an M.D. from UCSF. He completed his internal medicine residency at the Brigham and Women’s Hospital and his fellowship in oncology at the Dana-Farber Cancer Institute.
Its earnings per share (EPS) expected to touch remained 60.00% for this year while earning per share for the next 5-years is expected to reach at 7.00%. VAR has a gross margin of 42.10% and an operating margin of 13.00% while its profit margin remained 10.70% for the last 12 months.
According to the most recent quarter its current ratio was 1.3 that represents company’s ability to meet its current financial obligations. The price moved ahead of -5.17% from the mean of 20 days, -14.41% from mean of 50 days SMA and performed -15.18% from mean of 200 days price. Company’s performance for the week was 0.95%, -18.36% for month and YTD performance remained -4.20%.